With the completion of the Human Genome Project and advances in next-generation sequencing, numerous studies have identified significant associations between GCKR variants and metabolic diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and familial hypertriglyceridemia [11,12,13]. This evidence concerns the gene GCKR and metabolic dysfunction-associated steatotic liver disease.